CASTLEFORD, England, May 8, 2012 /PRNewswire/ --
We are pleased to announce the day-one patent expiry launch of generic atorvastatin film-coated tablets in 10mg, 20mg, 40mg and 80mg strengths.
Atorvastatin is a generic version of Lipitor® (atorvastatin) from Pfizer. It is indicated in the treatment of hypercholesterolaemia, and in the prevention of cardiovascular disease.
Atorvastatin is available immediately in the award-winning Teva 360 livery, in packs of 28.
Kim Innes, Commercial Director at Teva said: "We're delighted to be able to launch atorvastatin in the UK on the day its patent expires. As the leading generics company in the country and with the widest portfolio of our competitors, we've now launched seventeen products this year including now ten day-one patent expiries.
"Millions of prescriptions are written each year in the UK for atorvastatin, and the availability of the generic will save the NHS millions of pounds each year. It and other patent expiries provide pharmacy the opportunities for increasing margins and keeping costs down, and also mean we at Teva continue to do our bit in saving the NHS over £9bn a year through the availability of generic medicines."
New or existing customers can order through their local Teva Territory Sales Manager, by completing the online form, or calling on 0800 085 8621.
To find out more about Teva UK Limited, visit http://www.tevauk.com.
For media enquiries, contact the Teva UK Limited Media team on 01977 628500, or email email@example.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
Stefan Ingolfsson Communications Specialist
Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX
Mobile: +44(0)7809-595-072 Direct: +44(0)1977-628-642 Mobex: 88616
SOURCE Teva UK Limited